Biomarker: F079-IgE Gluten

Overview

F079-IgE Gluten measures immunoglobulin E (IgE) antibodies in blood that recognize gluten-containing wheat proteins. IgE is involved in immediate hypersensitivity reactions, including urticaria, gastrointestinal symptoms, respiratory symptoms, and anaphylaxis. A high result indicates sensitization to the tested gluten preparation, while a low or undetectable result makes sensitization less likely but does not independently exclude wheat allergy. The test is clinically useful as part of an evaluation for suspected IgE-mediated wheat allergy or wheat-dependent exercise-induced anaphylaxis, but results must be interpreted with the clinical history because sensitization alone does not confirm symptomatic allergy.

Clinical Use Cases

Supports evaluation of suspected immediate IgE-mediated wheat allergy.
Contributes to assessment of wheat-dependent exercise-induced anaphylaxis.
Helps evaluate patients with reproducible symptoms occurring minutes to a few hours after wheat or gluten exposure.
May be used with clinical history, skin-prick testing, and, when necessary, a supervised oral food challenge.
Helps distinguish suspected wheat allergy from non-IgE-mediated conditions such as celiac disease or non-celiac gluten sensitivity, although it does not diagnose those conditions.
May be used during follow-up to assess changing sensitization, but serial concentrations should not be used alone to determine whether a patient can safely consume wheat.

Specimen Types

Serum.
Plasma may be accepted by some validated immunoassays, according to the laboratory’s requirements.
Whole blood is used for cellular assays such as basophil activation testing, but this is not the usual specimen for F079-specific IgE measurement.

Measurement Methods

Fluorescence enzyme immunoassay or enzyme-linked immunoassay for quantitative allergen-specific IgE.
Other validated immunoassay platforms for serum allergen-specific IgE.
Skin-prick testing with wheat or gluten-containing extracts is a related in-vivo assessment, not a direct measurement of F079-IgE.
Component-resolved testing for individual wheat allergens, such as omega-5 gliadin, gliadins, or glutenins, may provide additional information when whole-wheat or gluten testing is inconclusive.
Basophil activation testing is an adjunctive research or specialized clinical method and is not equivalent to serum F079-specific IgE measurement.

Test Preparation and Influencing Factors

Fasting is generally not required for a serum-specific IgE test.
Antihistamines usually do not affect serum-specific IgE results, although they can suppress skin-prick test responses.
Patients should not stop prescription or nonprescription medicines unless instructed by a healthcare professional.
The result should be interpreted with the timing, reproducibility, severity, and route of symptoms after wheat or gluten exposure.
A positive result indicates IgE sensitization and does not by itself establish clinical allergy or predict reaction severity.
Cross-reactivity, particularly with grass-pollen allergens, can produce low-level positive results in people who tolerate wheat.
Commercial gluten or wheat extracts may not represent all clinically relevant wheat allergens, so a negative result does not exclude wheat allergy when the history is strongly suggestive.
Exercise, alcohol, nonsteroidal anti-inflammatory drugs, heat, and infection can act as cofactors in wheat-dependent exercise-induced anaphylaxis and should be documented.
A supervised oral food challenge remains the reference procedure when the history and sensitization testing are discordant or inconclusive.